Advanced Diagnostic Platform CathWorks offers an innovative FFRangio system that transforms coronary angiography into an objective, wire-free decision-making tool, providing a significant clinical advantage for hospitals seeking to improve CAD treatment outcomes.

Growing Industry Recognition Recent awards and high-profile nominations, such as the finalist position at the 2025 Octane High Tech Awards, showcase strong industry validation and potentially increased demand from medical institutions looking for cutting-edge cardiac solutions.

Strategic Collaborations Partnerships with healthcare providers like HT Global Industries Limited and Hhmglobal, along with significant investment from Medtronic, position CathWorks for broad market reach and provide avenues to leverage existing distribution channels.

Robust Funding & Revenue With over 46 million dollars in funding and an annual revenue estimated between 10 and 50 million dollars, CathWorks demonstrates solid financial backing and growth potential, enabling targeted expansion into new markets or hospitals.

Market Expansion Opportunities Participation in major industry events like EuroPCR 2025 and ongoing enrollment in global clinical studies such as ALL-RISE highlight opportunities to engage with leading cardiology centers and expand adoption among progressive healthcare providers.